vial tirzepatide – 60 mg 22% body weight Tirzepatide — Weight Loss |

Nearly half of people who say they have been diagnosed with diabetes (45%) report currently using a GLP-1 medication, as do three in ten (29%) adults who say theyve been diagnosed with heart disease and about a quarter (23%) of those who report being diagnosed as overweight or obese in the past five years

[74] Gastrointestinal effects could include nausea, dyspepsia, and increased risk of peptic ulceration, particularly with concurrent use of other ulcerogenic medications

Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists

I came up with the idea for this blog after Halloween, when a colleague came in and said, "I heard you like M&Ms

PMID: 18469287.